Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, indicating a minor update to the page's revision history. It does not modify the study data or the user-facing content of the page.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.6.5 replaces v3.6.4, indicating a deployment/update of the site's underlying tooling. This update does not change the study data, eligibility criteria, results, or visible content on the page.SummaryDifference0.0%

- Check49 days agoChange DetectedThe Study Details page updated its revision label from v3.6.3 to v3.6.4, representing a small page patch rather than new or altered study information.SummaryDifference0.0%

- Check71 days agoChange DetectedThe page revision tag was updated to v3.6.3, indicating a small publishing update to the page's version rather than changes to the study data or displayed content.SummaryDifference0.0%

- Check78 days agoChange DetectedThe study details page revision tag was updated from v3.6.0 to v3.6.2, signaling a small maintenance update to the page’s underlying system.SummaryDifference0.0%

- Check92 days agoChange DetectedThe study record now indicates it is not actively enrolling participants and adds new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study); the revision tag was updated to v3.6.0 and the Intervention/Treatment heading formatting was adjusted.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.